beta-amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding.

In Alzheimer's disease (AD), beta-amyloid (Abeta) is deposited in extracellular matrices, initiating an inflammatory response and compromising cellular integrity. Epidemiological evidence and studies in animal models provide strong evidence that high-saturated-fat and/or cholesterol-rich diets exacerbate cerebral amyloidosis, although the mechanisms for this are unclear. Abeta contains hydrophobic domains and is normally bound to lipid-associated chaperone proteins. In previous studies, we have put forward the notion that Abeta is a regulatory component of postprandial lipoproteins (i.e., chylomicrons) and that aberrations in kinetics may be a contributing risk factor for AD. To explore this further, in this study, we utilized an immunohistochemical approach to determine if Abeta or its precursor protein is expressed in epithelial cells of the small intestine -- the site of chylomicron biogenesis. Wild-type mice were fed a low-fat or a high-fat dietary regime and sacrificed, and their small intestines were isolated. We found that, in mice fed low-fat chow, substantial Abeta/precursor protein was found exclusively in absorptive epithelial cells of the small intestine. In contrast, no Abeta/precursor protein was found in epithelial cells when mice were fasted for 65 h. In addition, we found that a high-fat feeding regime strongly stimulates epithelial cell Abeta/precursor protein concentration. Our findings are consistent with the notion that Abeta may serve as a regulatory apolipoprotein of postprandial lipoproteins.

[1]  G. Watts,et al.  Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? , 2001, American journal of physiology. Endocrinology and metabolism.

[2]  T. Wisniewski,et al.  Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. , 2002, Vascular pharmacology.

[3]  A. Hofman,et al.  Dietary fat intake and the risk of incident dementia in the Rotterdam study , 1997, Annals of neurology.

[4]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[5]  A. Saunders,et al.  Sequestration of Amyloid β‐Peptide a , 1993 .

[6]  T. Iwatsubo,et al.  Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Abeta42. , 1998, The Journal of biological chemistry.

[7]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[8]  S. Gandy,et al.  Mutant Presenilin 1 Increases the Levels of Alzheimer Amyloid β‐Peptide Aβ42 in Late Compartments of the Constitutive Secretory Pathway , 2000 .

[9]  D. Borchelt,et al.  Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins , 1995, Neuron.

[10]  J. Leverenz,et al.  Diet-induced hypercholesterolemia enhances brain A&bgr; accumulation in transgenic mice , 2002, Neuroreport.

[11]  R. Martins,et al.  Relationship between lipid metabolism and plasma concentration of amyloid precursor protein and apolipoprotein E , 1999 .

[12]  M. Hussain,et al.  Signposts in the assembly of chylomicrons. , 2001, Frontiers in bioscience : a journal and virtual library.

[13]  Y. Ihara,et al.  Intracellular Generation and Accumulation of Amyloid β-Peptide Terminating at Amino Acid 42* , 1997, The Journal of Biological Chemistry.

[14]  B. Zlokovic,et al.  Blood-brain barrier transport of circulating Alzheimer's amyloid beta. , 1993, Biochemical and biophysical research communications.

[15]  S. Estus,et al.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing. , 1992, Science.

[16]  Carol J Bult,et al.  Antibodies that label paraffin-embedded mouse tissues: a collaborative endeavor. , 2004, Toxicologic pathology.

[17]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[18]  R. Doms,et al.  Alzheimer's Aβ(1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells , 1997, Nature Medicine.

[19]  F. Panza,et al.  Dietary fatty acids intake: possible role in cognitive decline and dementia , 2005, Experimental Gerontology.

[20]  T. Olivecrona,et al.  Conversion of chylomicrons into remnants. , 1998, Atherosclerosis.

[21]  B. Hyman,et al.  Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma* , 1996, The Journal of Biological Chemistry.

[22]  M. Hussain,et al.  Assembly and Secretion of Chylomicrons by Differentiated Caco-2 Cells , 1999, The Journal of Biological Chemistry.

[23]  J. Beaulieu,et al.  Human cell models to study small intestinal functions: Recapitulation of the crypt‐villus axis , 2000, Microscopy research and technique.

[24]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Weisgraber,et al.  Effects of Polymorphism on the Lipid Interaction of Human Apolipoprotein E* , 2003, Journal of Biological Chemistry.

[26]  T. Wisniewski,et al.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. , 1993, The Biochemical journal.

[27]  M. Emmerling,et al.  Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. , 1998, Biochemical and biophysical research communications.

[28]  Stephen W. Scheff,et al.  Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol , 1994, Experimental Neurology.

[29]  A. James,et al.  The incorporation and metabolism of amyloid-beta into chylomicron-like lipid emulsions. , 2003, Journal of Alzheimer's disease : JAD.

[30]  T. Iwatsubo,et al.  Subcellular Compartment and Molecular Subdomain of β-Amyloid Precursor Protein Relevant to the Aβ42-promoting Effects of Alzheimer Mutant Presenilin 2* , 2001, The Journal of Biological Chemistry.

[31]  P. Tso,et al.  Incorporation of chylomicron fatty acids into the developing rat brain. , 1994, The Journal of clinical investigation.

[32]  M. M. Greevenbroek,et al.  Chylomicron synthesis by intestinal cells in vitro and in vivo. , 1998 .

[33]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[34]  A. Legrand,et al.  A Sensitive Time-Resolved Immunofluorometric Assay for the Measurement of Apolipoprotein B in Cerebrospinal Fluid. Application to Multiple Sclerosis and Other Neurological Diseases , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[35]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[36]  T. Wisniewski,et al.  Alzheimer's disease and soluble Aβ , 1994, Neurobiology of Aging.

[37]  H. Shao,et al.  Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. , 1999, Journal of molecular biology.